Multiple Sklerose (MS)
- Geschlecht Beides
- Alter von 18 bis 54
- BMI von 18 bis 30
- Berechnen Sie Ihren BMI hier
Multiple Sklerose (MS)
Clinical trial of a new compound that is being developed for the treatment of multiple sclerosis (MS)
The research physician about this research
This trial consists of two parts (part 1 and part 2) and each of these parts is composed of two periods. You can only participate in one part of the trial and you will receive the compound twice: once per period.
In this trial, cerebrospinal fluid will be collected in each part via a lumbar puncture. This procedure will be performed at four different moments during the trial (twice per period). A fine needle will be inserted at the space between two vertebrae in the lower back. This procedure will be performed by an experienced specialist (anesthesiologist).
Für Deutschland: Bitte beachten Sie: Die Arzneimittelstudien finden im niederländischen Groningen statt. Sie müssen Englisch oder Niederländisch sprechen, verstehen und lesen können, um an einer Studie teilnehmen zu können.
Important information about this study
- In part 1, the compound will be given both times after you have not eaten anything for at least 10 hours, including the night.
- In part 2, the compound will be given once after fasting overnight and once after the consumption of a meal.
- This order can also be inverted (fasting – meal consumption or meal consumption–fasting).
Group 2a1/2a2 VOLL |
2 × 5 Tage Aufenthalt 16 Jul 2023 bis einschl. 20 Jul 2023 6 Aug 2023 bis einschl. 10 Aug 2023 |
kurzer Besuch 22 jul 2023 25 jul 2023 29 jul 2023 1 aug 2023 12 aug 2023 15 aug 2023 19 aug 2023 22 aug 2023 29 aug 2023 5 sep 2023 19 sep 2023 3 okt 2023 17 okt 2023 |
nakeuring 7 nov 2023 |
€ 7.213 |
Group 1a1/1a2 VOLL |
2 × 5 Tage Aufenthalt 13 Aug 2023 bis einschl. 17 Aug 2023 20 Aug 2023 bis einschl. 24 Aug 2023 |
kurzer Besuch 19 aug 2023 26 aug 2023 29 aug 2023 2 sep 2023 5 sep 2023 12 sep 2023 19 sep 2023 3 okt 2023 17 okt 2023 31 okt 2023 |
Nachuntersuchung 21 nov 2023 |
€ 6.553 |
Group 2b1/2b2 VOLL |
2 × 5 Tage Aufenthalt 17 Sep 2023 bis einschl. 21 Sep 2023 8 Okt 2023 bis einschl. 12 Okt 2023 |
kurzer Besuch23 sep 2023 26 sep 2023 30 sep 2023 3 okt 2023 14 okt 2023 17 okt 2023 21 okt 2023 24 okt 2023 31 okt 2023 7 nov 2023 21 nov 2023 5 dec 2023 19 dec 2023 |
Nachuntersuchung 9 jan 2024 |
€ 7.213 |
Who can participate?
- You are a healthy male or female.
- You are at least 18 and no more than 54 years old.
- Your Body Mass Index (BMI) is at least 18 and no more than 30 kg/m2.
- Both non-smokers and light smokers or occasional smokers (up to a maximum of 5 cigarettes per day) are allowed to participate in this clinical trial. Smoking is not allowed during your stay in our research facility.
Note:
- You cannot participate in the trial if you have participated in another clinical trial in the 90 days prior to the first compound administration in this clinical trial (counting from the follow-up visit). For some trials this term will be 6 months, this will be discussed during your telephone screening.
- For this trial, you cannot (have) receive(d) an influenza and/or COVID-19 vaccine within 6 weeks prior to the start and during this trial.
- To determine if you are suitable to participate in this trial, you will undergo a medical screening. Depending on availability, this can be performed in Groningen or in Utrecht. The medical screening consists of two separate visits. After the regular medical screening at ICON there will be an additional visit to perform an MRI scan.
As a female you can only participate if you are not pregnant, not breastfeeding and meet one of the following conditions:
- You are using hormonal contraception (for example the contraceptive pill or intra-uterine device containing hormones) in combination with a condom;
- You have passed the menopause (no periods for at least 12 months);
- You have been sterilized or your male partner has been sterilized;
- You are not sexually active according to your lifestyle;
- You are only sexually active with a partner of the same sex.
As a male you can only participate if you meet one of the following conditions:
- You are using a condom in combination with an additional contraception method used by your female partner;
- You have been sterilized or your female partner is sterilized or has passed the menopause (no periods for at least 12 months);
- You are not sexually active according to your lifestyle;
- You are only sexually active with a partner of the same sex.
Compensation
Based on the number of short visits between the two periods (depending on the group you will participate in) you will receive the following compensation:
- 1 short visit between both periods: You will receive a gross compensation of € 6553 for participation in one of the groups.
- 3 short visits between both periods: You will receive a gross compensation of € 6993 for participation in one of the groups.
- 4 short visits between both periods: You will receive a gross compensation of € 7213 for participation in one of the groups.
Travel expenses will be reimbursed based on the distance traveled (€ 0.21 net per kilometer) with a minimum of € 13 and a maximum of € 176.40 (840 kilometers) per round trip, regardless of the mode of transportation.
Period of stay and research
For both parts, the trial consists of 2 periods during which you will stay in the research facility in Groningen (location van Swietenlaan 6) for 5 days (4 nights ) in each period. There are 1 to 4 short visits between both periods. This is different between each group. The second period will be followed by 10 short visits. The follow-up visit will take place during your last short visit.
Note: You must be available for all dates to be able to participate in this clinical trial.
Explanation video
In this trial, cerebrospinal fluid is collected via a lumbar puncture. Researchers can extract important information from this fluid. A lumbar puncture is a safe procedure that is performed by an experienced specialist (anaesthesiologist). In this video we explain how this works.